Approximately 70% of patients with life-threatening diseases treatable with allogeneic blood stem cell transplantation do not have matched related donors. The National Marrow Donor Program (NMDP) was established in 1986 to provide human leukocyte antigen (HLA)-matched, volunteer unrelated donors for these patients. The NMDP performs this task by maintaining a registry of more than 4.9 million volunteer donors of marrow and peripheral blood stem cells (PBSC) and 12 cord blood banks containing more than 25,000 units of umbilical cord blood.
researchers in the field of unrelated stem cell transplantation. The NMDP research program develops and promotes research aimed at increasing opportunities for and improving outcomes of unrelated donor stem cell transplants. NMDP resources available to researchers include:
The largest database of HLAtyped individuals in the world (more than 4.9 million volunteer donors). Outcome, histocompatibility data, donor search, and donation sideeffects data on approximately 90% of the more than 16,000 unrelated donor stem cell transplants the NMDP has coordinated since 1987. The largest unrelated stem cell donor and recipient HLA database in the world (more than 7,600 paired samples).
The NMDP, in collaboration with the International Bone Marrow Transplant Registry (IBMTR) and the EMMES Corporation, recently received a 5-year NIH grant to coordinate a newly established Blood and Marrow Transplant Clinical Research Network. Funding for this network is being provided by both the National Heart, Lung and Blood Institute and the National Cancer Institute. When the network begins operations, a data coordinating center will manage a national network of centers performing clinical trials focused on hematopoietic stem cell transplantation. Additional goals of the network include developing consensus guidelines for diagnosing, monitoring, and grading important transplant-related end points, and the development and use of novel study designs to increase the efficiency and scientific validity of clinical trials in blood and marrow transplantation. The NMDP and Unrelated Donor Stem Cell Transplantation Approximately 75% of the stem cell transplants facilitated by the NMDP are for patients with some form of leukemia. Indications for unrelated donor stem cell transplant are constantly changing. Since 1999, NMDP-facilitated transplants for adults with acute myelogenous leukemia have increased 66%, and transplants for myelodysplastic syndromes have increased by 50%. Since the development of imatinib mesylate (Gleevec) to treat chronic myelogenous leukemia (CML), NMDP-facilitated transplants for CML have decreased by 45%.
Current research is exploring the use of reduced-intensity (nonmyeloablative) regimens in allogeneic stem cell transplantation. This has resulted in an increase in the number of stem cell transplants for non-Hodgkin's lymphoma, multiple myeloma, and hemoglobinopathies such as sickle cell disease. [1, 2] Researchers are also investigating the use of stem cell transplantation in breast cancer [3, 4] and renal cell carcinoma. [3, 5] Table 2 shows the diseases for which unrelated stem cell donor transplants have been performed by transplant centers in the NMDP Network Obtaining an NMDP-Facilitated Stem Cell Transplant Initiating a preliminary search of the NMDP Registry to locate an HLAmatched donor or umbilical cord blood is free and available to any physician. Interpreting the results of a preliminary search and efficiently moving forward through the many steps to a transplant requires an understanding of the clinical aspects of stem cell transplantation and knowledge of the operations of the NMDP. The HLA System Lymphocytes differentiate between self and nonself cells by examining the HLA antigens expressed on the surface of cells. To prevent graft rejection and other posttransplant complications, stem cell donors and recipients must be closely HLA matched. [6] The HLA antigens are encoded on the short arm of human chromosome 6, on a segment called the major histo-compatibility complex (MHC). There are 3.5 million bases in the MHC, but only a small number are currently matched in stem cell transplantation. The relevant portions of the MHC are further divided into two regions-class I and class II. Class I antigens (HLA-A, -B, and -C) and class II antigens Page 5 of 12
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Published on Cancer Network (http://www.cancernetwork.com) (HLA-DRB1, -DP, and -DQ) are the antigens most frequently examined when matching potential stem cell donors and transplant recipients.
The NMDP requires that donors and patients have no more than a one-antigen mismatch at the HLA-A, -B or -DRB1 locations. Because there are two HLA antigens at each of these three locations, a perfect match is referred to as a 6 of 6 match, and a one-antigen mismatch is termed a 5 of 6 match. Using this terminology, the NMDP will allow a 5/6 match or a 6/6 match for marrow and peripheral blood stem cell transplants, but not a 4/6 match or less. The NMDP will allow a 4/6 match for cord blood transplants, provided the mismatched antigens are not at the same loci. This less stringent HLA matching for cord blood is permitted because of the lowered immunologic competence of cord blood T cells. [7] [8] [9] Some transplant centers require additional matching at the HLA-C, -DP, and/or DQ loci. Newer DNA-based methods of HLA typing have proven to be more accurate than serologic methods and have largely superseded them. [ 
10] Impact of HLA Match on Transplant Outcome
In allogeneic stem cell transplantation, the degree of donor/recipient HLA match is an important factor in engraftment, the development of graftvs-host disease (GVHD), and overall survival. [11, 12] The association of HLA class I allele disparity with graft failure was examined by the Seattle group, who retrospectively analyzed data from 21 patients experiencing graft failure and 42 case-matched controls. Complete allele-level matching for class I was identified in 45% of controls and 10% of graft failure cases. [13] The effect of the number of HLA disparities was subsequently studied in unrelated-donor stem cell transplant for CML patients. Among allele-matched donors/recipients and donors/recipients mismatched for a single class I allele, the graft failure rate was 2%. When two or more class I disparities at HLA-A, -B, and/or -C were present, the graft failure rate increased to 29%. [14] In unrelated-donor stem cell transplantation, the risk of clinically significant GVHD is also influenced by the extent of HLA disparity between the donor and recipient. GVHD is a potentially life-threatening complication involving an immunologic reaction in recipients that is mediated by the transplanted T cells. Searching the NMDP Registry for an Unrelated Donor Any physician can submit a preliminary search request free of charge by submitting to the NMDP the patient's name and address, age, sex, race/ethnic group, disease diagnosis, disease status, and HLA If the preliminary review of the NMDP Registry reveals one or more potentially matched donors and/or cord blood units, and if the physician and patient decide to pursue a stem cell transplant, a more formal search of the NMDP Registry can be initiated. At this point, charges are assessed to the patient's transplant center, because a formal search of the NMDP Registry involves additional blood tests of volunteer donors or cord blood units. Only physicians at NMDP-affiliated transplant centers can perform formal searches of the NMDP Registry, so the patient must now be referred to an NMDP-affiliated transplant center if he or she is not at one already. Before a transplant can proceed, a potential donor undergoes confirmatory typing, an additional higher-resolution HLA typing to confirm the results of the original HLA typing. To speed this process, the NMDP uses stored blood samples from volunteer donors whenever possible, but sometimes a fresh blood draw is needed. At this point, a potential marrow or PBSC donor is contacted by phone by NMDP donor center staff to ensure that the donor is in good health and willing to donate. Obtaining a confirmatory typing result from a stored cord blood unit requires sending an aliquot from the unit to a central laboratory under contract with the NMDP. Once the HLA typing of the donor is confirmed, and if the physician and patient decide to proceed to transplant, the NMDP arranges for the donor to be counseled about the risks involved in the donation process. The potential donor receives a physical exam to ensure he/she is medically fit to donate. If the potential donor agrees to donate, the NMDP informs the transplant center and a donation date is scheduled at an NMDP collection or apheresis center closest to where the donor lives. If a cord blood unit is selected, the NMDP arranges for the unit to be shipped to the transplant center in a "dry shipper" that keeps the cord blood at the temperature of liquid nitrogen. The average turnaround time from a request to the shipment of a cord blood unit is 7 to 10 days. Selection of Donors/ Stem Cell Source For more than 30 years, bone marrow has been the standard source of stem cells used in transplantation. In the last decade, however, the use of two new sources of stem cells has grown rapidly. There has been a steady increase in the use of allogeneic PBSCs, from 20% of all allogeneic transplants in 1995 to 40% in 2000. The use of cord blood has also risen rapidly. In allogeneic recipients less than 20 years of age without sibling donors, the use of cord blood has increased from < 5% in 1995 to 15% in 2000. [15] Depending on their source, stem cells have different kinetics of hematologic recovery and different probabilities of eliciting GVHD. Engraftment of PBSC is on average faster than engraftment of marrow or cord blood stem cells, although incidence and severity of chronic GVHD is typically greater in PBSC recipients. [16, 17] Cord blood generally has longer engraftment times but leads to a lower incidence and severity of GVHD. [9, 18] Transplant physicians must therefore consider stem cell source in their donor selection decisions. Blood Stem Cell Procurement The NMDP coordinates unrelated donor stem cell transplant using all three sources of stem cells-bone marrow, PBSC, and umbilical cord blood. Bone marrow and PBSC are obtained from the NMDP Registry of more than 4.9 million potential volunteer donors. More than 25,000 umbilical cord blood units are available from our growing partnership with cord blood banks.
Marrow Harvest
Bone marrow harvest is one method of obtaining hematopoietic stem cells performed at NMDP collection centers. It has been used less frequently in recent years, since PBSC have become an alternative source of hematopoietic stem cells. Marrow is harvested from the posterior iliac crests while the donor is under general or spinal anesthesia. Large-bore needles are used to aspirate the marrow into syringes rinsed with a heparin-containing solution. The cortical bone is penetrated, and 5 to 10 mL of marrow is aspirated and trans-ferred to a container with anticoagulant solution. The aspiration needle is advanced several millimeters, rotated 90 o , and the process is repeated. Several aspirations can be made through a single bone puncture, and the bone may be punctured multiple times from a single skin entry site. The amount of marrow collected is determined by the transplant center and is based on the recipient's weight. However, NMDP regulations prohibit collections > 20 mL/kg of a donor's weight. A typical collection involves 200 to 300 marrow aspirations through two skin incisions. [19] The volume collected is determined by the nucleated cell count in the collected marrow and by the recipient's weight. The target is usually 2 to 4 * 10 8 nucleated cells per kilogram of the recipient's weight. [19] Marrow harvests are typically very well tolerated by donors, although side effects such as localized pain, fatigue, and nausea do occur. Serious complications are rare. Couriers transport the donated marrow stem cells to the recipient's transplant center. PBSC
Collection
Many transplant centers have turned to PBSC as the primary source of stem cells for allogeneic transplants. A primary advantage of the PBSC approach is its rapid and durable trilineage engraftment. Although PBSC are capable of hematopoiesis, peripheral blood in its steady state does not contain adequate numbers of stem cells to allow for efficient collection. To collect an adequate number of stem cells in the least number of apheresis sessions, it is necessary to stimulate the production of PBSC through mobilization. Unrelated PBSC collection must be performed using regimens that pose the least possible risk to the donor yet provide the highest quality graft to the recipient. Mobilization of unrelated volunteer donors is performed using a granulocyte colony-stimulating factor (G-CSF, Neupogen). Most healthy people can tolerate G-CSF administered daily at 5 to 10 μg/kg of donor weight for 5 to 6 days; higher doses do not reliably increase the number of CD34-positive cells and can result in more severe side effects. [19] Apheresis typically starts on day 4 or 5, with a second collection on day 6 if the first collection is inadequate. The number of circulating CD34-positive progenitor cells usually peaks on day 5 or 6 of G-CSF injections. [20] The extent of stem cells mobilized and time of peak mobilization can vary widely among individuals. However, sufficient numbers can reliably be collected from most donors by administering a single daily dose of G-CSF at 7 to 10 μg/kg subcutaneously for 4 to 6 days, followed by one to three apheresis procedures starting on day 3 to 5. is important that transplant centers educate patients, families, and community physicians about the potential for further complications. Close follow-up and rapid intervention when needed provide these patients with the best chance for long-term survival. Summary Since its founding in 1986, the NMDP has facilitated more than 16,000 transplants for patients with blood disorders such as leukemia and aplastic anemia, as well as immune system disorders and genetic disorders. The donors who provided the blood stem cells for these transplants came from the NMDP Registry, the world's largest and most diverse registry of potential blood stem cell donors. Initiating a search of the NMDP Registry for an HLA-matched unrelated donor is as simple as submitting to the NMDP a patient's HLA typing results along with basic demographic and disease information. If a suitable donor is identified, the NMDP coordinates the steps needed to bring the donated stem cells-whether they be marrow, PBSC, or cord blood-to a patient. After reading this article, physicians should have a greater understanding of the complicated process needed to bring about an unrelated donor stem cell transplant. A better understanding of the role the NMDP plays in unrelated donor stem cell transplantation reduces the chances that physicians and patients will have unrealistic expectations about the process. To initiate a preliminary search of the NMDP Registry, contact the NMDP Office of Patient Advocacy toll-free at 1-888-999-6743. A preliminary search request form can also be submitted via the NMDP website: www.marrow.org
